# SillaJen

Source: https://onco.cc/companies/sillajen/  
OnCo record `sillajen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SillaJen is a South Korean company that began with viruses engineered to infect and kill cancer cells. Its newest medicine, BAL0891, is a tablet-type drug that blocks two enzymes cancer cells need to divide, and the FDA gave it orphan drug status for acute myeloid leukaemia in 2026.

## Summary

SillaJen, Inc. has its head office at 106 Cheonggyecheon-ro in Seoul, a research centre in Gwanggyo, a pharmaceutical division in Suwon and an office in San Diego, according to its website, which describes it as developing oncolytic immunotherapeutics. Its pipeline page lists BAL0891, a dual TTK and PLK1 inhibitor (the page cites a 2022 Basilea presentation as a source), alongside oncolytic vaccinia virus programmes. The company says BAL0891 is in a phase 1 dose-escalation trial in relapsed or refractory solid tumours (NCT05768932, which ClinicalTrials.gov lists as also enrolling relapsed or refractory acute myeloid leukaemia). On 24 August 2026 the FDA granted orphan drug designation for the treatment of acute myeloid leukaemia to a product the database describes as a small-molecule mitotic checkpoint inhibitor with dual inhibition of TTK and PLK1; the company's website headlines the designation as one for BAL0891.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: SillaJen, Inc.; SillaJen Inc.; SillaJen Biotherapeutics
- HQ: Seoul
- Type: biotech
- Website: https://www.sillajen.com/

## Notes

- The FDA database record names the product only by description; the company's own news headline, 'FDA Designates BAL0891 as Rare Drug for Acute Myeloid Leukemia', ties it to BAL0891. The site links a Yahoo Finance quote for 215600.KQ (KOSDAQ). Read on 4 November 2026.

## Sources

- Official website: https://www.sillajen.com/
- BAL0891 pipeline page: https://www.sillajen.com/eng/sub/pipeline_bal0891.html
- FDA orphan designation, acute myeloid leukaemia, 24 August 2026: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1162426
- ClinicalTrials.gov: BAL0891 phase 1 (NCT05768932): https://clinicaltrials.gov/study/NCT05768932

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [MPS1 (TTK)](https://onco.cc/targets/ttk/), [PLK1](https://onco.cc/targets/plk1/)
- drugs: [BAL0891](https://onco.cc/drugs/bal0891/)

---
JSON: https://onco.cc/api/v1/entities/sillajen.json